Shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) have earned an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.
Brokerages have set a 12-month consensus price objective of $24.25 for the company, according to Zacks. Zacks has also assigned Takeda Pharmaceutical an industry rank of 67 out of 256 based on the ratings given to related companies.
Several analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Friday, May 17th. ValuEngine lowered shares of Takeda Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Wednesday, May 15th. Finally, Goldman Sachs Group reiterated a “buy” rating on shares of Takeda Pharmaceutical in a research note on Tuesday, March 19th.
TAK traded up $0.12 during trading on Friday, hitting $17.84. 943,597 shares of the company’s stock were exchanged, compared to its average volume of 1,204,188. The company has a current ratio of 1.22, a quick ratio of 0.82 and a debt-to-equity ratio of 0.92. The firm’s 50 day moving average price is $17.42. Takeda Pharmaceutical has a fifty-two week low of $15.50 and a fifty-two week high of $21.95. The company has a market cap of $27.87 billion, a PE ratio of 34.98 and a beta of 0.69.
Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Tuesday, May 14th. The company reported $0.13 earnings per share (EPS) for the quarter. Takeda Pharmaceutical had a net margin of 10.60% and a return on equity of 12.18%. The firm had revenue of $3.51 billion during the quarter. As a group, research analysts expect that Takeda Pharmaceutical will post 0.44 earnings per share for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Adelphi Capital LLP bought a new stake in shares of Takeda Pharmaceutical in the 1st quarter worth $188,841,000. FMR LLC grew its position in Takeda Pharmaceutical by 9,453,973.8% during the first quarter. FMR LLC now owns 7,563,259 shares of the company’s stock valued at $154,063,000 after buying an additional 7,563,179 shares during the period. Northern Trust Corp grew its position in Takeda Pharmaceutical by 23.5% during the first quarter. Northern Trust Corp now owns 4,218,850 shares of the company’s stock valued at $85,939,000 after buying an additional 803,851 shares during the period. Parametric Portfolio Associates LLC grew its position in Takeda Pharmaceutical by 114.9% during the first quarter. Parametric Portfolio Associates LLC now owns 3,312,996 shares of the company’s stock valued at $67,486,000 after buying an additional 1,771,039 shares during the period. Finally, Mondrian Investment Partners LTD grew its position in Takeda Pharmaceutical by 4.8% during the first quarter. Mondrian Investment Partners LTD now owns 3,012,870 shares of the company’s stock valued at $60,257,000 after buying an additional 139,000 shares during the period. Hedge funds and other institutional investors own 11.44% of the company’s stock.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.
Recommended Story: Return On Assets
Get a free copy of the Zacks research report on Takeda Pharmaceutical (TAK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.